Skinny Labels and Orange Book in Focus During Intellectual Property Discussions
By Editorial Team
During a recent meeting of patent litigators specializing in pharmaceuticals and biotechnology, key issues in the industries were addressed. Discussions included potential reforms to skinny label law, challenges related to position-switching in litigation, decisions on when to list patents in the U.S. Food and Drug Administration’s Orange Book, and insights on the limited impact of new policies at the U.S. Patent and Trademark Office.
The meeting highlighted the importance of staying informed and engaged in the fast-paced world of intellectual property law. With over 200 articles published daily across various topics, industries, and jurisdictions, a Law360 subscription provides access to expert analysis, real-time alerts, judge information, and a vast archive of searchable articles.
Key players in the legal industry, including law firms like Axinn Veltrop, Fish & Richardson, Goodwin Procter, and government agencies such as the Food and Drug Administration and the U.S. Patent and Trademark Office, were also mentioned during the discussions.
For professionals looking to stay ahead in the field of intellectual property law, a Law360 subscription offers valuable insights and resources to navigate complex legal landscapes with confidence and efficiency.
